|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Proteo Inc. (PTEO.OB) / Proteo Biotech AG (PTEO.OB) Commissions The Manufacture Of Elafin To GMP-Standards In Belgium; Elafin For Clinical Testing
10/19/2005 5:13:14 PM
KIEL, Germany--(BUSINESS WIRE)--April 7, 2005--Elafin, the anti-inflammatory protein of PROTEO Biotech AG, will be subjected to clinical testing in the very near future, representing a further step on its way to being licensed as a drug. The authorities demand strict standards for the manufacture of medicines for clinical testing, and the GMP (Good Manufacturing Practice) production of Elafin for the upcoming trials has to comply with a large number of rules and regulations.
"That's why we have chosen Eurogentec S.A. in Belgium to produce the required amounts of Elafin for us," commented Walter J. Thomsen, CEO of PROTEO Biotech AG. Thomsen added that the manufacture of Elafin to GMP standards is too complex for a company like PROTEO. By contrast, Eurogentec, situated in Liege, Belgium has 290 employees as well as the necessary infrastructure and experience to produce biologically and pharmaceutically active substances quickly and in sufficient amounts for the approaching clinical trials. The collaboration of the two companies was sealed on the 23rd of March 2005. The production of Elafin is due to begin on the 11th of April and will be completed in the first week of July.
|
|
|
|
|
|
|
|
|
|
|